Renovo inks $875M deal for scarring drug

Demonstrating a big appetite for potential blockbusters, Shire has agreed to pay Renovo $75 million up front along with a $50 million equity payment as part of an $875 million deal for the exclusive development and commercialization rights to Juvista, a scarring drug. The deal includes $700 million in scheduled milestone payments. The drug is intended for use after surgery and cosmetic procedures as well as for burn victims. The deal demonstrates a bullish estimate of the potential market for Juvista. Researchers say the drug could garner $4 billion a year in the U.S. market alone. The therapy is in development and could be approved in 2011. The partnership covers countries outside of the EU.

"This is a novel biopharmaceutical drug candidate that we believe could become a leader in the market for prevention and treatment of scarring, a market served by specialist physicians--as are all of Shire's markets," said Shire CEO Matthew Emmens.

- check out the release for more
- here's the report from The Times

Related Articles:
Renovo CEO bullish on partnership prospects. Report
Renovo sees shares jump on first day. Report
Shire snares New River Pharma in $2.6B buyout. Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.